Viridian Therapeutics
VRDN

$14.09

4.6%

Market Cap: $900M

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Employees: 94

Healthcare Medical Laboratories

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

146% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 28

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

1% more funds holding

Funds holding: 134 [Q1] → 136 (+2) [Q2]

5.37% less ownership

Funds ownership: 114.26% [Q1] → 108.9% (-5.37%) [Q2]

28% less capital invested

Capital invested by funds: $1.26B [Q1] → $904M (-$352M) [Q2]

42% less call options, than puts

Call options by funds: $3.99M | Put options by funds: $6.92M

80% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 1 (-4) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$27

92%

upside

Avg. target

$31

122%

upside

High target

$42

198%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Needham Serge Belanger 45% 1-year accuracy 40 / 89 met price target	113%upside $30	Buy Reiterated	30 Aug 2024
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target	148%upside $35	Outperform Reiterated	28 Aug 2024
HC Wainwright & Co. Douglas Tsao 46% 1-year accuracy 48 / 104 met price target	92%upside $27	Buy Reiterated	15 Aug 2024
Oppenheimer Leland Gershell 55% 1-year accuracy 27 / 49 met price target	99%upside $28	Outperform Reiterated	12 Aug 2024
Wedbush Laura Chico 44% 1-year accuracy 33 / 75 met price target	198%upside $42	Outperform Reiterated	29 Jul 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.27 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ending June 30, 2024. “Our team continues to execute across the board as shown by the progress we have made this quarter, and we are proud to report solid progress in our TED portfolio, with both VRDN-001 pha.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,500 shares of the company's common stock to t.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Top 3 Health Care Stocks You May Want To Dump This Quarter

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump This Quarter

3 Biotech Names With Potential Catalysts By Year End

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.

3 Biotech Names With Potential Catalysts By Year End

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED. THRIVE-2 enrolled 188 patients globally and exceeded the enrollment target of 159 patients due to patient demand. Approximately 40% of the enrolled patients were from U.

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Zacks Investment Research

Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?

Viridian Therapeutics (VRDN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?

3 Small-Cap Stocks With Explosive 2X Growth Potential

Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, investors are speculating which high-growth small-cap stocks may thrive.

3 Small-Cap Stocks With Explosive 2X Growth Potential

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 538,000 shares of the company's common stock to.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety would be considered a win, but there is potential for better efficacy and safety.

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

See News Rankings